November 22, 2004

Ambry Genetics Launches New Website
www.ambrygen.com Offers Expanded Content for Medical Professionals and Customers

IRVINE, CA (November 22, 2004) – AMBRY GENETICS, a leading genetic testing company, announced that it has launched a redesigned and enhanced corporate Web site www.ambrygen.com, which offers comprehensive information on the Company’s innovative tests for cystic fibrosis, pancreatitis, colon cancer (HNPCC) and research testing offerings.

"Because the importance of accurate genetic assessment cannot be underestimated, we have a unique opportunity to educate and inform site visitors while making it easy for healthcare professionals to conduct business with us," said Charles L. M. Dunlop, CEO of Ambry Genetics. "Our new site showcases the unprecedented knowledge and experience we have gained over the years with thousands of known disease-causing mutations and previously unreported mutations. It also reflects our commitment to building successful relationships with all our customers, potential partners and prospective employees."

Ambrygen.com features extensive audience-specific information organized in expanded Test Directory, Ordering, Improved Billing and Resources sections. The site design has been optimized for faster loading and efficient navigation and features informative Corporate and Current News sections.

Besides being a valuable resource for healthcare professionals, the Ambry Genetics website can assist a patient in their research, so they can ask the right questions and participate actively in decision-making with caregivers. Comprehensive genetic testing provides a solid basis for proper therapy and for the practice of preventative medicine.

AMBRY GENETICS

Ambry Genetics is a worldwide leader in specialized genetic testing. The proprietary Ambry Test™ combines scanning and sequencing technologies to analyze a gene’s entire coding region plus surrounding critical introns. Capable of identifying more than 99% of the known disease-causing mutations of the CFTR gene, the company’s reputable Cystic Fibrosis test has an unrivaled detection rate of over 96% across all ethnic groups. The Company also created the world’s first and only comprehensive genetic test for three principal genes (PRSS1, SPINK1 and CFTR) associated with Chronic and Hereditary Pancreatitis. Ambry Genetics most recent development detects mutations of the most significant genes (MLH1, MSH2) causing hereditary colon cancer, significantly optimizing patient management and risk assessment. Headquartered in Irvine, California, the Company’s advancements are providing precise, cost effective methods to aid in disease definition and early, more accurate diagnosis. Several academic and pharmaceutical research projects are underway, including expanded population statistical analysis and the development of assays for other genes. Website: www.ambrygen.com.